Virtual Drug Development Inc. (aka VDDI) works in drug development, focusing on product opportunities where general proof-of-principle has already been established in pre-clinical or human testing, and where the products are novel and offer significant potential advantages to products currently in the market or in development. An Internet-based company, the firm's business model organizes around in-licensing and development of therapeutics indications in the areas of infectious disease, cancer, and cardiovascular disease. Product development areas include acute coronary syndrome, PCI, antifungal, antimicrobial, anthrax, NAD synthetase inhibitors for anthrax infections, agro-terrorism, new peptide pharmaceuticals announcement and InterLink, and biotechnologies. The firm is structured to pursue fast track approval for drugs in the areas of cancer, cardiovascular disease and infectious disease. Utilizing electronic data capture and data submission to regulatory authorities, the firm is headquartered in Tennessee,VDDI also has offices in Huntsville, AL; Ann Arbor, MIand Research Triangle Park,NC
